When do the patents on DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER expire, and when will generic DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	dextrose; sodium chloride	INJECTABLE;INJECTION	018229-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
B Braun	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	dextrose; sodium chloride	INJECTABLE;INJECTION	019631-014	Feb 24, 1988		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: October 6, 2026

Dextrose 10% and sodium chloride 0.45% injection, commonly called D10 half-normal saline or D10 0.45% NaCl, is a mature generic intravenous fluid. Its commercial value comes from recurring hospital demand, not patent exclusivity. The product has low scientific differentiation, limited pricing power and meaningful manufacturing barriers because sterile injectable production requires validated facilities, container systems, quality controls and reliable supply of flexible plastic bags.

The financial trajectory is stable in normal supply conditions but can change sharply during shortages. Product-level revenue is generally not disclosed by manufacturers, so the most reliable analysis uses hospital utilization, market access, capacity, contract pricing and supply continuity rather than standalone sales figures.

What is dextrose 10% and sodium chloride 0.45% injection used for?

Dextrose 10% and sodium chloride 0.45% injection is an intravenous solution containing 10 grams of dextrose and 0.45 grams of sodium chloride per 100 mL. A 1,000 mL container therefore contains approximately 100 grams of dextrose and 4.5 grams of sodium chloride, subject to the labeled formulation and presentation.

The product is used when patients require intravenous calories, glucose and sodium chloride in a controlled fluid regimen. Clinical use can include:

Maintenance or replacement fluid therapy
Treatment or prevention of hypoglycemia in selected settings
Pediatric and neonatal fluid management under clinical supervision
Perioperative and inpatient care
Situations requiring dextrose with a lower sodium concentration than isotonic saline

The solution is hypertonic relative to plasma because of its dextrose concentration. The prescribing information warns that administration requires attention to serum glucose, sodium, fluid balance and infusion rate. It is not interchangeable with plain 5% dextrose or 0.45% sodium chloride in every clinical circumstance. [1]

What container sizes are commercially relevant?

Common presentations include flexible plastic containers in 250 mL, 500 mL and 1,000 mL sizes, although the available configuration depends on the manufacturer, hospital contract and market. Larger-volume bags generally dominate adult inpatient use, while smaller containers are more relevant to pediatrics, emergency medicine and specialized dosing needs.

The container is part of the commercial product. Hospitals assess port design, overwrap, storage requirements, labeling, tubing compatibility and ease of use alongside formulation and price.

How large is the market for D10 0.45% sodium chloride?

The addressable market is a narrow segment of the broader U.S. large-volume parenteral and intravenous-fluid market. It competes with:

Dextrose 5% in water
Dextrose 10% in water
Sodium chloride 0.45%
Sodium chloride 0.9%
Dextrose and sodium chloride combinations at other concentrations
Balanced crystalloid solutions
Pharmacy-compounded or institution-specific alternatives in limited settings

Demand is anchored by hospital admissions, intensive care utilization, emergency department volume, surgical activity and pediatric care. The product is usually purchased through group purchasing organizations, hospital systems, wholesalers and distributor contracts.

Unlike specialty pharmaceuticals, the market does not depend on a single prescriber brand. Formulary and purchasing decisions usually prioritize:

Reliable availability
Unit price and contract terms
Container functionality
FDA-approved labeling
Vendor redundancy
Product quality and recall history

Exact U.S. market share and revenue for D10 0.45% NaCl are not generally reported in public company filings. Manufacturers typically aggregate the product into broader intravenous solutions, generic injectables or hospital products categories.

What is the competitive landscape?

The principal competitive groups are large sterile-injectable manufacturers with established plastic-container infrastructure. Potential suppliers in the U.S. market include Baxter, B. Braun, Fresenius Kabi and ICU Medical, subject to current product availability, manufacturing status and presentation.

Competitive factor	Market effect
Product formulation	Low differentiation
FDA approval	Required for commercial substitution
Plastic bag capacity	Major supply constraint
Hospital contracts	Determines recurring volume
Manufacturing redundancy	Reduces shortage exposure
Container design	Can influence conversion decisions
Brand loyalty	Limited outside supply-sensitive accounts
Patent protection	Generally immaterial for this mature solution

Competition is often supplier-based rather than molecule-based. A hospital may use multiple vendors for intravenous fluids to reduce exposure to a single manufacturing disruption.

How does D10 0.45% NaCl compare with competing IV fluids?

Product	Primary demand driver	Competitive position
Dextrose 10% in water	Glucose delivery without sodium	Direct clinical substitute in some uses
Dextrose 5% in water	Lower dextrose load and maintenance use	Broader routine demand
Sodium chloride 0.45%	Hypotonic sodium and fluid replacement	Competes when dextrose is not required
Sodium chloride 0.9%	Isotonic volume replacement	Much larger general-use market
D10 0.45% NaCl	Combined glucose and lower sodium	Narrower but clinically specific demand
Balanced crystalloids	Volume replacement with electrolyte balance	Alternative in selected inpatient and surgical use

The product is less exposed to substitution when the clinical requirement includes both dextrose and sodium. It is more exposed when clinicians can use separate or lower-concentration solutions without compromising treatment.

What drives pricing and financial performance?

D10 0.45% NaCl is a low-price, high-volume hospital product. Financial performance depends on manufacturing utilization and contract retention more than list price.

Pricing structure

Net pricing is shaped by:

Group purchasing organization agreements
Hospital-system contracts
Distributor discounts
Annual volume commitments
Shortage-related spot purchases
Container and shipping costs
Federal and state procurement programs
Product presentation and bag size

Public list prices can materially overstate realized revenue. Hospitals often purchase under confidential contracts, and the same product can have different net prices across health systems.

Margin profile

Gross margins are constrained by:

Sterile manufacturing validation
Environmental monitoring
Water-for-injection systems
Plastic resin and container production
Labor and quality-control costs
Freight and warehousing
Regulatory compliance
Recall and remediation exposure

The product has limited active-ingredient cost. The economic bottleneck is sterile capacity, packaging and supply-chain execution. A manufacturer with high utilization and efficient bag production can achieve acceptable margins at relatively low unit prices. A plant operating below capacity or experiencing quality failures can produce weak economics despite stable demand.

When does D10 0.45% sodium chloride lose exclusivity?

Dextrose 10% and sodium chloride 0.45% injection is generally a mature generic product without commercially meaningful patent exclusivity. Its market structure is determined by FDA approval, manufacturing capacity, procurement contracts and supply reliability.

What is the Orange Book status?

The Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Mature IV solutions marketed by multiple suppliers typically do not have a practical Orange Book patent barrier that prevents competing manufacturers from entering the formulation market. [2]

For this product category:

Patent expiry is generally not the key entry issue.
Paragraph IV litigation is not normally the central competitive risk.
ANDA approval and manufacturing readiness matter more than patent clearance.
Product-specific Orange Book status can vary by sponsor, presentation and approval pathway.
Hospital conversion may take longer than regulatory approval because of validation, formulary review and supply qualification.

No meaningful patent estate is generally associated with the basic D10 0.45% NaCl formulation itself. Any protection may instead relate to container technology, manufacturing equipment, packaging or unrelated proprietary processes.

Are there formulation patents or method-of-use patents?

The basic formulation is old and widely known. Commercially relevant intellectual-property risk is more likely to arise from:

Flexible-container design
Multilayer plastic construction
Port and closure systems
Manufacturing processes
Filling and sterilization methods
Packaging configurations
Delivery-system compatibility

These rights would not necessarily block a competitor from selling the same active formulation in a different compliant container.

Method-of-use patents are also unlikely to create a durable barrier for the broad clinical uses of a standard dextrose and sodium chloride infusion. Use-specific claims could theoretically affect a narrow indication, but the product’s commercial demand is based on general hospital fluid management rather than a patented therapeutic method.

Which companies are challenging the product market?

Competition is usually indirect. Manufacturers do not need to challenge a branded innovator through patent litigation because the product is already a generic, multi-source injectable.

The relevant competitive actions are:

New ANDA approvals
Re-entry after manufacturing remediation
Additional plastic-bag capacity
Contract wins with hospitals and group purchasing organizations
Formulary conversion
Importation or alternate manufacturing-site qualification
Product discontinuation or presentation rationalization

The FDA’s approval database and drug shortage database are more relevant to market entry than patent litigation databases for this product class. [3,4]

What is the FDA regulatory status?

D10 0.45% NaCl injection is regulated as a prescription sterile injectable drug. Commercial products must meet FDA requirements for:

Sterility
Strength and identity
Particulate control
Container-closure integrity
Manufacturing-process validation
Stability
Labeling
Adverse-event reporting
Current good manufacturing practice

FDA approval does not guarantee uninterrupted supply. Sterile injectable products can experience shortages from contamination investigations, equipment failures, raw-material constraints, quality-control problems or plant shutdowns. FDA has repeatedly identified manufacturing concentration and limited backup capacity as important contributors to injectable-drug shortages. [4,5]

What generic entry risks exist?

The risk of new generic entry is high in principle because the formulation is mature and technically familiar. Actual entry is slower because sterile manufacturing is capital-intensive.

Entry factor	Risk assessment
Patent barrier	Low
Formulation complexity	Low
Sterile manufacturing complexity	High
Container qualification	Moderate to high
Regulatory approval	Moderate
Hospital conversion	Moderate
Supply-chain execution	High
Price erosion after entry	Moderate to high

A new supplier can obtain approval yet struggle to secure hospital volume because purchasing organizations value supply history and operational reliability. Conversely, a manufacturing disruption can rapidly improve pricing for remaining suppliers.

What patent litigation affects D10 0.45% sodium chloride?

There is no established, product-defining patent litigation pattern comparable to branded drugs with high-value Paragraph IV challenges. Litigation risk is more likely to involve:

Product liability
Contamination or quality claims
Contract disputes
Procurement disputes
Trade secrets
Container or manufacturing technology

Paragraph IV litigation would be unusual for the basic formulation. A patent dispute involving a plastic container or delivery component would likely affect a narrower commercial feature rather than the entire D10 0.45% NaCl market.

What is the outlook for shortages and supply continuity?

Supply continuity is the central commercial risk. The product is inexpensive, but hospitals cannot easily operate without dependable IV-fluid availability. A shortage can produce:

Allocation controls
Purchase limits
Emergency sourcing
Substitution with other dextrose or saline products
Higher distributor prices
Increased freight costs
Reduced hospital choice
Temporary share gains for available suppliers

Shortages can also increase working-capital requirements because manufacturers and distributors hold more inventory. Hospitals may qualify alternate suppliers, which can permanently alter market share after the shortage ends.

The long-term outlook is stable demand with periodic volatility. Capacity investments, dual sourcing and improved inventory planning should reduce the frequency of severe disruptions, but sterile injectable manufacturing remains vulnerable to single-site failures.

What is the financial trajectory for manufacturers?

Base case

Revenue remains broadly stable, with modest volume growth tied to hospital utilization and population aging. Net prices remain constrained by procurement contracts. Margin expansion depends on plant efficiency, production scale and reduced shortage-related costs.

Upside case

An established supplier gains share after a competitor experiences a shortage, recall or plant shutdown. The supplier may secure new contracts, improve capacity utilization and retain part of the converted volume after the market normalizes.

Downside case

Price competition intensifies as additional suppliers enter, while raw-material, labor and freight costs rise. A quality event can create remediation expense, lost contracts and regulatory scrutiny. The low unit value limits the ability to pass through higher costs.

Scenario	Revenue effect	Margin effect	Main driver
Stable supply	Low single-digit growth potential	Stable	Recurring hospital demand
Competitor shortage	Temporary increase	Positive	Share capture and utilization
New entrant capacity	Flat to declining	Negative	Contract price pressure
Manufacturing disruption	Decline or lost volume	Negative	Recall, remediation or allocation
Hospital consolidation	Mixed	Negative risk	Greater buyer bargaining power

How does D10 0.45% NaCl compare with higher-value drug products?

The product has a fundamentally different investment profile from specialty pharmaceuticals and biologics.

Attribute	D10 0.45% NaCl	Specialty drug or biologic
Patent dependence	Low	High
Clinical differentiation	Limited	Often significant
Unit price	Low	High
Prescriber brand effect	Low	High
Manufacturing risk	Sterile capacity	Complex active ingredient or biologic process
Substitution	Relatively high	Often limited
Revenue disclosure	Usually aggregated	Often reported by product
Litigation exposure	Low patent risk	Potentially substantial

The investment thesis is therefore operational. Value depends on manufacturing reliability, hospital access, scale, product breadth and contract execution.

Key Takeaways

Dextrose 10% and sodium chloride 0.45% injection is a mature, multi-source generic IV solution.
The product has limited formulation differentiation and generally no meaningful patent-exclusivity barrier.
Orange Book, Paragraph IV and branded patent litigation are less important than FDA approval, sterile capacity and hospital contracting.
Product-level revenue is usually not separately disclosed by manufacturers.
Financial performance is driven by volume, capacity utilization, contract pricing and supply continuity.
Shortages can create temporary pricing power and share gains for suppliers with available inventory.
Plastic-container manufacturing, sterility assurance and validated filling capacity are the principal operational barriers.
The long-term outlook is stable but exposed to periodic supply disruptions and margin pressure.

FAQs About Dextrose 10% and Sodium Chloride 0.45% Injection

Is D10 0.45% NaCl the same as D10 in water?

No. D10 in water contains dextrose without sodium chloride. D10 0.45% NaCl contains both dextrose and sodium chloride and has different electrolyte and osmotic properties.

Is D10 0.45% NaCl a branded drug?

Usually no. It is primarily marketed as a generic prescription injectable by manufacturers of hospital intravenous solutions.

Does D10 0.45% NaCl have biosimilar competition?

No. Biosimilars apply to biological products. D10 0.45% NaCl is a chemically defined small-molecule infusion solution.

Can hospitals substitute another IV fluid during a shortage?

Clinical substitution depends on the patient’s glucose, sodium, fluid and electrolyte requirements. Hospitals typically use approved shortage protocols and physician or pharmacy review rather than treating all IV solutions as interchangeable.

What is the most important competitive advantage in this market?

Reliable sterile manufacturing and uninterrupted delivery are usually more valuable than formulation innovation. Hospital buyers often favor suppliers that can maintain supply across multiple bag sizes and facilities.

References

DailyMed. (n.d.). Dextrose and sodium chloride injection, USP: Prescribing information. U.S. National Library of Medicine.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
U.S. Food and Drug Administration. (n.d.). Drug shortages database.
U.S. Food and Drug Administration. (2019). Drug shortages: Root causes and potential solutions. FDA Drug Shortages Task Force.

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER at DailyMed

Drug Class	Osmotic Laxative
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER Drug Patent Profile

When do Dextrose 10% And Sodium Chloride 0.45% In Plastic Container patents expire, and when can generic versions of Dextrose 10% And Sodium Chloride 0.45% In Plastic Container launch?

AI Deep Research

Questions you can ask:

Summary for DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

Pharmacology for DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

US Patents and Regulatory Information for DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

Dextrose 10% and Sodium Chloride 0.45% in Plastic Container: Market Dynamics, Pricing, Supply Risk and Financial Outlook